Alexion Pharmaceuticals, Inc.

Today, we’re concluding an impactful few days at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), where we had the privilege of connecting with researchers and clinicians who share our commitment to advancing care for those living with neuromyelitis optica spectrum disorder (#NMOSD). Our leading research in NMOSD, including a presentation recognised as part of this year’s “Best of ECTRIMS,” underscore our relentless drive to improve outcomes in this rare neurological disease. We also proudly showcased our short film, Rare Connections in NMOSD, highlighting the challenges of living with NMOSD, the power of connection and the resilience of the NMOSD community. Watch here: http://spr.ly/6045AdZtc

aHUS is a type of thrombotic microangiopathy (TMA), a group of severe and potentially life-threatening rare disorders that cause blood clots and damage to blood vessels, which can lead to organ failure and death. See the signs, symptoms & complications of TMA ⬇️ #aHUSDay

We’re excited to be at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain. We look forward to sharing our latest research in neuromyelitis optica spectrum disorder (#NMOSD) and screening our one-of-a-kind short film, Rare Connections in NMOSD, to elevate patient voices and deepen understanding of this rare neuromuscular disease.

Today on #aHUSDay, we recognise and honour those living with atypical haemolytic uraemic syndrome. We are inspired by the strength and resilience of the aHUS community and remain dedicated to improving care for those affected by this severe and devastating disease. #aHUS24Sept

Neuromyelitis optica spectrum disorder (#NMOSD) is a rare and debilitating autoimmune disease characterised by unpredictable relapses or attacks. Discover more about this condition and its impact below.

Hypophosphatasia (#HPP) can affect males and females of all ages, with certain symptoms more common based on a person’s age.

The promise of this innovation extends beyond diagnosis—it enables early action and decision making. Learn how Alexion and partners are actively working to transform the diagnostic journey through advancing genomic newborn screening: http://spr.ly/6049ATmyB

Genomic newborn screening holds the potential to transform the diagnostic landscape and rare disease care. Read to learn more: http://spr.ly/6042ATlf6

With more than 400 million people worldwide living with a rare disease, and 10,000 rare diseases known to exist today, rare diseases are not as rare as we may think. Learn more https://lnkd.in/efAHhJc6

Haematopoietic stem cell transplant-associated thrombotic microangiopathy is a type of TMA, a group of severe and potentially life-threatening rare disorders that cause blood clots & damage to the walls of the smallest blood vessels, that occurs following HSCT. Learn more below.